A research team led by Andrew Armstrong, MD, MSc, identifies new targets for treating non-clear cell renal carcinoma
In 2016, a global multi-institutional team of investigators led by Duke Cancer Institute member and professor of Medicine, Surgery, Pharmacology and Cancer Biology, Andrew Armstrong, MD, MSc, reported in The Lancet their finding that a small-molecule drug (sunitinib) they’d trialed in patients with metastatic non-clear cell renal cell carcinoma (NC-RCC) significantly increased the length of progression-free and overall survival over the alternative standard-of-care biologic agent (everolimus).